Status:
COMPLETED
CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Acute Kidney Injury
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Since the emergence of the new strain of betacoronavirus (SARS-CoV-2) and its important clinical repercussions, it has been described that patients with its associated pneumonia (COVID-19) have high r...
Detailed Description
After randomization, patients will be allocated to one of two groups: Control group (n = 45): patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagu...
Eligibility Criteria
Inclusion
- Confirmed or probable SARS-CoV-2 infection;
- Presence of acute kidney injury with indication and agreement between ICU and nephrology teams for the introduction of renal continuous venous venous hemodialysis.
Exclusion
- Hypersensitivity to any of the substances used in the study (Citric acid dextrosol 2.2% and unfractionated heparin);
- Previous diagnosis of coagulopathy or thrombophilia;
- Contraindication to the use of unfractionated heparin by the assistant team;
- Risk of citrate poisoning - (Lactate\> 30mg / dL, RNI\> 2.5, Total bilirubin\> 15mg / dL);
- Pregnancy
Key Trial Info
Start Date :
June 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 3 2021
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT04487990
Start Date
June 29 2020
End Date
April 3 2021
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of São Paulo General Hospital
São Paulo, São Paulo, Brazil, 05403-010